Consensus and Controversies Between Pain and Addiction Experts on the Prevention, Diagnosis, and Management of Prescription Opioid Use Disorder.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
Historique:
pubmed:
20
11
2019
medline:
29
4
2021
entrez:
20
11
2019
Statut:
ppublish
Résumé
Prescription opioid use disorder (POUD) is an established public health crisis in many countries, and current evidence indicates it is a growing problem in Europe. Many specialists play a role, including pain and addiction medicine specialists, in the diagnosis and management of POUD, but neither group can fully address these patients' needs alone. The purpose of this consensus process was to bring together experts from pain and addiction medicine to examine the positions of both specialties. In all, 13 international pain medicine, addiction medicine, and addiction psychiatry experts convened a meeting to formulate a set of consensus statements on the diagnosis and management of POUD. The statements were further refined by a wider group of 22 European expert clinicians. At a second meeting of all 35 participants, a set of controversy statements was also developed to recognize some of the key areas of divergent opinion. There was a high level of agreement between pain and addiction specialists. Key themes that emerged were the need to strengthen interdisciplinary communication, a desire for greater education and training for clinicians in both specialties, and mutual acknowledgment of the importance of multidisciplinary management of POUD. The blurred line between poorly managed pain and POUD was also a subject of much discussion, reflecting the difficulties in defining and diagnosing this complex condition.
Identifiants
pubmed: 31743124
doi: 10.1097/ADM.0000000000000577
pii: 01271255-202002000-00001
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-11Références
American Society of Addiction Medicine. Definition of Addiction; 2011. Available at: http://www.asam.org/for-the-public/definition-of-addiction. Accessed September, 2015.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th editionWashington, DC: American Psychiatric Association; 2000.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. Arlington, VA: American Psychiatric Association; 2013.
Bateman C. Is your prescribing serving a hidden addiction? S Afr Med J 2013; 103:359–361.
Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011; 12:657–667.
Blake H, Leighton P, Van der Walt G, Ravenscroft A. Prescribing opioid analgesics for chronic non-malignant pain in general practice - a survey of attitudes and practice. Br J Pain 2015; 9:225–232.
British Medical Association Board of Science. Prescribed drugs associated with dependence and withdrawal - building a consensus for action. Analysis report. London: British Medical Association; 2015.
Centers for Disease Control and Prevention. CDC Funding Helps States Combat Prescription Drug Overdose Epidemic; 2015. Available at: http://www.cdc.gov/media/releases/2015/p0904-cdc-funding.html. Accessed February 24, 2016.
Centers for Disease Control and Prevention. Understanding the Epidemic; 2018. Available at: https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed January 2016.
Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts. Manage Sci 1963; 9:458–467.
Degenhardt L, Bruno R, Lintzeris N, et al. Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. Lancet Psychiatry 2015; 2:315–322.
Dematteis M, Auriacombe M, D’Agnone O, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother 2017; 18:1987–1999.
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2014: Trends and Developments. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; May 2014.
Fischer B, Jones W, Rehm J. Trends and changes in prescription opioid analgesic dispensing in Canada 2005–2012: an update with a focus on recent interventions. BMC Health Serv Res 2014; 14:90.
Giraudon I, Lowitz K, Dargan PI, et al. Prescription opioid abuse in the UK. Br J Clin Pharmacol 2013; 76:823–824.
Han B, Compton WM, Blanco C, et al. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Ann Intern Med 2017; 167:293–301.
Jillson IA, Linstone HA, Turoff M. The National Drug-Abuse Policy Delphi: Progress Report and Findings to Date. TOC III.B.3. The Delphi Method: Techniques and Applications; 2002. Available at: http://is.njit.edu/pubs/delphibook/ch3b3.html. Accessed January, 2016.
Manchikanti L. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010; 13:401–435.
Miller NS, Sheppard LM, Colenda CC, et al. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med 2001; 76:410–418.
Modesto-Lowe V, Johnson K, Petry NM. Pain management in patients with substance abuse: treatment challenges for pain and addiction specialists. Am J Addict 2007; 16:424–425.
Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA 2017; 317:967–968. 7.
Office for National Statistics. Table 6a. Number of drug-related deaths where selected substances were mentioned on the death certificate, England and Wales, deaths registered between 1993–2013. Statistical Bulletin; 2013.
United Nations Office on Drugs and Crime. World Drug Report 2014. United Nations publication. June 2014.
van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev 2015; 8:3–14.
von der Gracht Heiko. Consensus measurement in Delphi studies: review and implications for future quality assurance. Technol Forecast Soc Change 2012; 79 (8):1525–1536.
World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization; 1992.
World Health Organization. Divisions of Mental Health. The ICD-10 Classification of Mental and Behavioral Disorders: Conversion Tables between ICD-8, ICD-9, and ICD-10. Geneva: World Health Organization. 1994.
World Health Organization. Management of Substance Abuse: Information Sheet on Opioid Overdose; 2018. Available at: https://www.who.int/substance_abuse/information-sheet/en/.